Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX (ORAL1069)
Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis
Sponsor: Pfizer
Listed as NCT01039688, this PHASE3 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by Pfizer, it has been updated 10 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Ahmedabad, India , Albany, United States , Austin, United States , Balatonfüred, Hungary , Bangalore, India , Bangkok, Thailand , Barnaul, Russia , Barranquilla, Colombia , Berlin, Germany and 123 more locations